Hormonal
GLP-1 receptor agonists (specifically liraglutide 3 mg/day) produce significant weight loss (8% mean reduction) and improve cardiovascular risk factors in obese and type 2 diabetic patients, though they carry a high discontinuation rate due to gastrointestinal side effects.
Liraglutide 3 mg daily is a highly effective pharmacological tool for weight loss, particularly for those with obesity or type 2 diabetes. It works by mimicking a gut hormone to increase satiety and slow digestion. While effective, it requires daily injections and careful dose titration to manage nausea. It is not a magic bullet; lifestyle changes are still required, and the high side-effect profile means it is not suitable for everyone.
In the 56-week study, given liraglutide 3 mg 4 times daily or placebo, weight loss was 8% in the liraglutide group (2.6% in the placebo group)... A recent meta-analysis showed that liraglutide had the highest discontinuation rate due to adverse effects among all FDA-approved obesity drugs (13% of patients).
Why this rating
Based on multiple large randomized controlled trials (SCALE series) with n > 2000, though it is a review paper summarizing them.
Source
Current pharmacological approaches in obesity treatment
Pelin TİRYAKİOĞLU et al. · DAHUDER Medical Journal · 2023
DOI 10.56016/dahudermj.1271677
More from this paper
- Pharmacological treatment of obesity is ineffective and potentially harmful if not combined with lifestyle changes (calorie restriction and increased energy expenditure), as evidenced by 'stop rules' that mandate discontinuation if <5% weight loss occurs within 12 weeks.Strong
- Combination therapies (e.g., Phentermine/Topiramate, Naltrexone/Bupropion) offer superior weight loss compared to monotherapy by targeting multiple pathways (appetite suppression and calorie absorption/reward), but carry higher risks of adverse effects and require strict monitoring.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →